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OBJECTIVE: Recently there has been increased emphasis on the
use of patient-reported outcomes (PRO) as a means of assessing
standard medical practice. This research was conducted to 
evaluate physicians’ perspectives on patient-reported data.
METHODS: We evaluate four programs designed to provide
feedback to physicians about their patients’ experiences with dif-
ferent medications. Patients prescribed a given medication vol-
untarily completed surveys about their symptoms and the impact
of symptoms on their lives before and after using the medica-
tion. The prescribing physician received a report summarizing
individual patient responses. A sample of physicians who par-
ticipated in at least one of these programs was interviewed about
their impressions of this feedback. This qualitative analysis sum-
marizes their responses. RESULTS: In total, 98 physicians were
interviewed. 39% were psychiatrists; 33% rheumatologists;
14% primary care; 12% neurologists; and 2% were pediatri-
cians. Generally, physicians felt that patient-reported informa-
tion was very important, particularly for guiding treatment
decisions and for monitoring treatment response and progress.
MDs liked receiving the information, oftentimes indicating,
“more information is always better,” though a few felt that
patient-reported data obtained in the ofﬁce setting are sufﬁcient.
Though many MDs had similar reactions to receiving patient-
reported data, some MDs, and psychiatrists in particular, con-
sistently commented that while information from patients is a
critical component of care, its accuracy might be suspect and
therefore must be examined in the context of objective, clinical
observations. Some reported that having patient feedback helps
them feel more comfortable with their prescribing. Physicians
were generally supportive of programs that let them help their
patients. CONCLUSIONS: Overall, physicians reported strong,
positive impressions of patient self-reported outcomes data.
Patient-reported data, viewed in the context of clinical presen-
tation, play a role in the diagnosis and treatment of illness, and
MDs are interested in programs and initiatives designed to give
them that information.
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OBJECTIVES: Highlight the diminishing utilization of pho-
totherapy as a treatment option for patients with moderate–to-
severe psoriasis. METHODS: Survey data collected by the
National Psoriasis Foundation between November and Decem-
ber 2004 was used to assess study objective. A total of 400 
interviews were held with psoriasis and psoriatic arthritis
respondents. Interviews were conducted over the phone (n = 188)
and online (n = 212). Respondents were screened for a mix of
gender and age. Severity of psoriasis, as measured by Body
Surface Area (BSA) was self-reported by patients as number of
patient’s palms covering area affected by psoriasis. BSA between
3% to 10% is indicative of moderate psoriasis, while greater
than 10% is indicative of severe psoriasis. The respondents were
queried on the medications they were currently using. Descrip-
tive data were generated to determine the demographic charac-
teristics of the study population and attain study objectives.
RESULTS: Approximately 75% of the population had moderate
to severe psoriasis as measured by BSA. Only about 9% of the
entire study population was on some form of phototherapy.
Almost 7% of respondents with moderate psoriasis (n = 86) were
on some form of phototherapy, while 11% with severe psoriasis
(n = 212) were on some form of phototherapy. CONCLUSIONS:
Phototherapy as a treatment option is underutilized. Photother-
apy is safer than other treatment strategies for psoriasis, with
efﬁcacy rates among the highest of all available treatment
options. Prior proven safety, efﬁcacy and cost effectiveness of
phototherapy makes it an attractive and beneﬁcial treatment
option that should be considered by patients, physicians, and
payors.
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OBJECTIVES: The FDA has recently issued a Public Health
Advisory to inform health care providers and patients regarding
potential carcinogenic risk from use of topical calcineurin
inhibitors: tacrolimus and pimecrolimus in atopic dermatitis
(AD), in spite of widespread belief in the medical community
about the safety of these medications. The objective of this study
was to analyze physician and patient related factors associated
with physicians’ prescribing of calcineurin inhibitors for AD in
a nationally representative sample of outpatient visits in US.
METHODS: This retrospective, cross sectional study utilized 
the National Ambulatory Medical Care Survey data from
2000–2003. Ofﬁce visits were considered to be AD related based
on presence of ICD-9 codes and if AD was reported as the reason
of visit or if any approved AD medication was prescribed.
Weighted logistic regression was used to examine predictors of
prescriptions of calcineurin inhibitors versus other AD medica-
tions. RESULTS: Topical calcineurin inhibitors constituted 7%
of the total 9 million AD medications prescribed in US outpa-
tient settings between 2000 and 2003. Almost 21,000 prescrip-
tions were written for children under the age of 2 years. The
odds of receiving a prescription for calcineurin inhibitors were
approximately 7 times (95%CI: 1.40–31.5) higher for patients
of white race as compared to other races. Patients who paid out
of pocket had higher odds of receiving a prescription of cal-
cineurin inhibitors as compared to other patients (OR: 4.66;
95%CI: 1.04–20.9). The odds of dermatologists prescribing cal-
cineurin inhibitors were 27 times (95%CI: 9.12–83.09) higher
as compared with non-dermatologists. CONCLUSIONS: Pre-
scribing trends indicate that the general medical community
seems to recognize the safety of tacrolimus and pimecrolimus
despite the warnings put out by the FDA. Rigorous safety and
efﬁcacy data collection may be warranted before the use of these
medications can be approved for children below two years.
